Magnesium supplementation in cancer patients under cisplatin treatment
Phase 2
- Conditions
- Condition 1: Hypomagnesaemia. Condition 2: Cancer types.Malignant neoplasms of lip, oral cavity and pharynx, Malignant neoplasms of digestive organs, Malignant neoplasms of respiratory and intrathoracic organs, Malignant neoplasms of bone and articular cartilage, Malignant neoplasms of mesothelial and soft tisHypomagnesaemia (Disorders of magnesium metabolismC00-C14, C
- Registration Number
- IRCT201112048299N1
- Lead Sponsor
- Oncopathology Research Center of Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
cancer diagnosis, beginning chemotherapy with Cisplatin drug, absence of renal disease and alcoholism, leukemia, non-consumption of drugs such as diuretics, aminoglycosides, cyclosporine and amphotericin B
Exclusion criteria: death before end of treatment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum magnesium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.
- Secondary Outcome Measures
Name Time Method Serum Creatinin level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Urea level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Calcium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Potassium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Sodium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.